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Abstract
Background: Atrial fibrillation can occur in up to 40% of patients undergoing coronary surgery.
Methods: We retrospectively analysed 103 consecutive coronary surgery patients under the care
of one surgeon between April 2003 and September 2003. These patients received 40 mg of sotalol
orally twice daily from the first post-operative day for 6 weeks and 2 g of magnesium intravenously
immediately post surgery and on the first post-operative day. We developed a propensity score for
the probability of receiving sotalol and magnesium after coronary surgery. 89 patients from the
sotalol and magnesium group were successfully matched with 89 unique coronary surgery patients
who did not receive either sotalol or magnesium with an identical propensity score.
Results: Preoperative characteristics were well matched between groups. There was no significant
difference with respect to in-hospital mortality between groups (sotalol and magnesium 1.1%
versus control 4.5%; p = 0.17). The incidence of atrial fibrillation in the sotalol and magnesium
group was 13.5% compared to 27.0% in the controls (p = 0.025).
Conclusion: The combination of sotalol and magnesium can significantly reduce the incidence of
post-operative atrial fibrillation following coronary surgery.
Introduction
Atrial Fibrillation is the most common complication fol-
lowing cardiac surgery with a reported incidence between
20% and 40% [1,2]. It usually occurs between the second
and fourth post-operative day. However, although this
complication occurs frequently, the mechanism behind
its development is less understood.
Numerous studies have identified and enumerated a vari-
ety of risk factors for the development of atrial fibrillation.
These include increased age, male gender, history of atrial
fibrillation, discontinuation of preoperative βeta-blocker
therapy, congestive heart failure, electrolyte depletion
(low potassium and magnesium), cardiopulmonary
bypass, left atrial dysfunction, severity of coronary artery
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disease, respiratory disease, and pulmonary vein venting
[1-7].
In an effort to prevent the occurrence of atrial fibrillation
in the post-operative period, various treatment modalities
have been implemented indicating its unclear pathophys-
iology. The key role of βeta blockers in prevention of atrial
fibrillation is well recognised in many randomised con-
trol trials [8,9]. Sotalol has an acceptable safety profile
and is emerging as a key drug in the prevention of this
complication [9,10]. The role of magnesium supplements
is less clear [11-17].
The present study was done to examine the beneficial role
of sotalol and magnesium prophylaxis in the prevention
of atrial fibrillation in routine coronary artery bypass graft
(CABG) surgery.
Materials and methods
Patient population
Between 1st April 2003 and 30th September 2003, 103 con-
secutive patients undergoing first time isolated CABG sur-
gery under the care of one surgeon (AYO) were routinely
administered sotalol and magnesium (see sotalol and mag-
nesium). These patients were matched to a control group
taken from the remaining 487 consecutive patients who
received first time isolated CABG surgery performed dur-
ing the same time period by other surgeons at our institu-
tion (see statistical methods).
Exclusions
Patients undergoing CABG that was in addition to heart
valve repair or replacement, resection of a ventricular
aneurysm or other surgical procedure were not included.
Also excluded were patients who had received previous
cardiac surgery or patients with a history of atrial arrhyth-
mias.
Data collection
Definitions and data collection methods are available
from http://www.nwheartaudit.nhs.uk. Data was col-
lected prospectively during the patient's admission as part
of routine clinical practice and entered into our cardiac
surgery registry on the variables listed in Table 1. Post-
operative atrial fibrillation, in-hospital mortality, and
length of hospital stay were also documented.
Sotalol and Magnesium
Patients received 40 mg of sotalol orally twice daily from
the first post-operative day for 6 weeks and 2 g of magne-
sium intravenously immediately post-coronary surgery
Table 1: Propensity-matched patient and disease characteristics
SM (n = 89) Control (n = 89) P Value
Age (years) 65.9 (59.2 – 70.1) 66.4 (59.2 – 71.9) 0.58
Female (%) 28.1 25.8 0.74
Body mass index (kg/m2) 27.1 (24.9 – 30.7) 27.1 (24.7 – 30.2) 0.81
Ejection fraction <30% 5.6 4.5 0.73
Triple-vessel disease (%) 75.3 74.2 0.86
Left main stem disease (%) 23.6 24.7 0.86
Angina class IV (%) 19.1 14.6 0.42
Diabetes (%) 23.6 29.2 0.39
Respiratory disease (%) 37.1 33.7 0.64
Renal dysfunction (%) 6.7 5.6 0.76
Peripheral vascular disease (%) 9.0 7.9 0.79
Current smoker (%) 20.2 20.2 >0.99
Previous myocardial infarction (%) 46.1 51.7 0.45
Hypercholesterolaemia (%) 95.5 95.5 >0.99
Hypertension (%) 57.3 55.1 0.76
Emergent procedure (%) 1.1 1.1 >0.99
Preoperative β-blockers (%) 66.3 64.0 0.75
Preoperative diuretics (%) 33.7 36.0 075
Preoperative heart rate (bpm) 69.1 (61.8 – 81.9) 70.3 (60.6 – 83.2) 0.57
Additive EuroSCORE 4 (2 – 5) 3 (2 – 5) 0.63
Number of grafts (n/patient) 3 (2 – 4) 3 (3 – 4) 0.61
Right-CAD (%) 76.4 71.9 0.49
LIMA (%) 95.5 96.6 0.69
CPB not used (%) 77.5 69.7 0.23
SM, Sotalol and Magnesium; CPB, Cardiopulmonary Bypass; EuroSCORE, European System for Cardiac Operative Risk Evaluation; CAD, Coronary 
Artery Disease; LIMA, Left Internal Mammary Artery. Categorical variables are shown as a percentage. Continuous variables are shown as a median 
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and on the first post-operative day. No patients from the
control group received sotalol and/or magnesium.
Outcome definitions
Post-operative atrial fibrillation was defined as the occur-
rence of new atrial fibrillation in the absence of pre-oper-
ative persistent or paroxysmal atrial fibrillation prior to
hospital discharge. In-hospital mortality was defined as
death within the same hospital admission regardless of
cause.
Statistical methods
In order to assess the effect of sotalol and magnesium, we
performed a propensity-matched cohort analysis [18]. To
do this, logistic regression was used to develop a propen-
sity score for sotalol and magnesium group membership.
The propensity score included the following variables:
age, sex, body mass index, respiratory disease, renal dys-
function, peripheral vascular disease, diabetes, severity of
angina and dysponea, hypertension, hypercholesterolae-
mia, smoking status, extent of disease, ejection fraction,
priority and use of cardiopulmonary bypass. The C statis-
tic, which is equivalent to the receiver-operating character-
istic curve, for the propensity model was 0.85. Sotalol and
magnesium patients were matched with control patients
who had an identical 5-digit propensity score. If this could
not be done, we then proceeded to a 4-, 3-, 2-, or 1-digit
match [19].
Continuous variables are shown as median with 25th and
75th percentiles and comparisons were made with Wil-
coxon rank-sum tests. Categorical variables are shown as
a percentage and comparisons were made with Chi-square
tests. A forward stepwise logistic regression analysis was
performed to identify risk factors for atrial fibrillation,
which was adjusted for the propensity score. In all cases a
P value < 0.05 was considered significant. All statistical
analysis was performed retrospectively with SAS for Win-
dows Version 8.2 (SAS Institute, Cary, NC).
Results
Of the 590 patients who underwent first time isolated
CABG at our institution during the study period, 28.0%
developed post-operative atrial fibrillation. Of the 103
patients who received sotalol and magnesium, 13.6%
developed atrial fibrillation compared to 31.0% in the
other patients (p < 0.001).
We were able to successfully match 89 patients who
received sotalol and magnesium to unique control
patients who did not. Of these, 5 (5.6%) were 5-digit
matches, 11 (12.4%) were 4-digit matches, 40 (44.9%)
were 3-digit matches, 24 (27.0%) were 2-digit matches,
and 9 (10.1%) were a 1-digit match. The patient and dis-
ease characteristics of the propensity-matched patients are
shown in Table 1.
There was no significant difference with respect to in-hos-
pital mortality between groups (sotalol and magnesium
1.1% versus control 4.5%; p = 0.17). The median length
of hospital stay in the sotalol and magnesium group and
control group were both 7 days [(25th and 75th percentiles:
6 to 9); p = 0.38].
The incidence of atrial fibrillation in the sotalol and mag-
nesium group was significantly lower compared to the
control group (Figure 1; p = 0.025); with an odds ratio of
0.42 (95% confidence interval: 0.19 to 0.91). The time of
occurrence of atrial fibrillation was similar between the
propensity-matched patients (Figure 2; p = 0.36).
A logistic regression analysis confirmed the beneficial
effect of sotalol and magnesium for reducing post-opera-
tive atrial fibrillation (Table 2).
Comment
Numerous studies have identified and enumerated a vari-
ety of pre-, intra- and post-operative risk factors [1-7],
with the aim of being able to change practice and reduce
Time of occurrence of post-operative atrial fibrillation in  propensity-matched patients Figure 2
Time of occurrence of post-operative atrial fibrillation in 
propensity-matched patients.
Propensity-matched incidence of atrial fibrillation Figure 1
Propensity-matched incidence of atrial fibrillation.Journal of Cardiothoracic Surgery 2006, 1:6 http://www.cardiothoracicsurgery.org/content/1/1/6
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the occurrence of atrial fibrillation. Several treatment
modalities have been investigated and have shown the
effectiveness of either prophylactic amiodarone or sotalol
in reducing this complication [9,10]. A meta-analysis, by
Wurdeman, concluded that compared to placebo, amio-
darone and sotalol were both effective in reducing post-
operative atrial fibrillation when used prohpylactically,
and that both were equally as effective as each other [9].
Sotalol has non-selective beta-blocking as well as class III
antiarrhythmic activity. In addition, it has no interaction
with the other beta blockers and so patients on pre-oper-
ative beta blockers other than Sotalol could be easily
switched to Sotalol for atrial fibrillation prophylaxis. Sota-
lol is associated with an increase in QTc interval but
reported incidence of torsades de pointes is very low. It
can sometimes induce profound bradycardia and hypo-
tension and should be avoided in low cardiac output
states.
Recently, Forlani and associates [20] found that the inci-
dence of atrial fibrillation after coronary operations was
significantly reduced by the administration of combina-
tion sotalol and magnesium therapy. They showed in a
randomised control trial of 207 consecutive CABG
patients, that administration of sotalol alone and magne-
sium alone significantly reduced the incidence of atrial
fibrillation, but more importantly, that when combined
together, the incidence of atrial fibrillation was reduced to
1.9%.
The presence of hypomagnesemia following cardiac sur-
gery is well described and has been shown to result in
higher atrial myocardium excitability and an increased
incidence of post-operative atrial fibrillation [14]. The
role of magnesium supplementation in reducing atrial
fibrillation has been extensively studied with varying
results.
Hazelrigg and colleagues [11] concluded that prophylac-
tic magnesium supplementation does not significantly
reduce atrial arrhythmias, and that the only benefit
occurred on the first post-operative day. Sinilarly, Parikka
[12] concluded that magnesium was not sufficient for
decreasing the incidence of atrial fibrillation. In a recent
randomised, double-blinded, placebo controlled trial,
Geertman found that magnesium in addition to sotalol,
was not more effective than sotalol alone in the preven-
tion of tachyarrhythmias after CABG. They also found that
serious bradyarrhythmias were observed in the magne-
sium-treated group of patients [13].
However, other reports in the literature have highlighted
the potential role of magnesium for reducing arrhythmias
post cardiac surgery [14-17]. Toraman and colleagues [15]
found that patients who received magnesium had a
reported incidence of atrial fibrillation of just 2% com-
pared to 21% in the control group. They point out that
several studies that failed to show the benefit of magne-
sium in reducing atrial fibrillation were not well ran-
domised with patients in the magnesium group being
older and having more preoperative palpitations and
arrhythmias [12]. Alghamdi [16] published a systematic
review and meta-analysis in 2005 which concluded that
intravenous magnesium was associated with a significant
reduction in the incidence of atrial fibrillation after coro-
nary artery bypass surgery, with a relative risk of 0.64
(95% CI 0.47 to 0.87; p = 0.004). Another meta-analysis
published in the same year by Miller and colleagues
showed a similar result with patients receiving magne-
sium having an atrial fibrillation rate of 18% compared to
28% in the control group (p < 0.001) [28].
Our own study confirms that the combination of sotalol
and magnesium can significantly reduce the incidence of
post-operative atrial fibrillation, with an incidence of
13.5% compared to 27% in a propensity-matched cohort.
But, unlike the study by Forlani [20], which had strict
exclusion criteria, this study is based on routine clinical
practice.
There are some limitations which need to be considered
when drawing conclusions from this report. The first is
that it is an observational study and therefore could have
some degree of selection bias. The retrospective nature of
the study cannot account for unknown variables affecting
the outcomes that are not correlated strongly with the var-
iables used in the propensity matching. Although, pro-
pensity score adjustment is no substitute for a properly
designed randomised control trial, retrospective compari-
sons with propensity score adjustment are more versatile
Table 2: Independent risk factors for post-operative atrial fibrillation
Odds Ratio † 95% Confidence Interval p Value
Female 0.17 0.05 – 0.61 0.006
SM group 0.39 0.18 – 0.89 0.025
Body mass index # 0.89 0.81 – 0.99 0.025
SM, Sotalol and Magnesium
† Adjusted for the propensity score
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and may be more widely applicable to routine clinical
practice [18]. Perhaps one of the most important limita-
tions is inextricable confounding caused by the sotalol
and magnesium patients being performed completely by
one surgeon. Even after careful application of multivariate
analyses and propensity-matching, it remains difficult to
distinguish between surgeon and treatment differences.
However these results are highly suggestive of a role for
the use of sotalol and magnesium in CABG and we are
already embarking on a randomised control trial to con-
firm or refute the findings of this observational study.
In conclusion, the combination of sotalol and magne-
sium can significantly reduce the incidence of post-opera-
tive atrial fibrillation following coronary artery bypass
surgery.
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